{"name":"Uwe Platzbecker","slug":"uwe-platzbecker","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQMkZXaHVJUWpsZ0tSV2NLZmlzMUtPeFhGNVpxVVZCOXlRZTg1d1gyZnl1RGNIRTFUbFlJNjNfLWdpcEVDOHAwN3pnZFpIQmx5WE5JTFJmOTExeDJPeGVrMjFmUGFKLTNJUEc2T0NqWm1tZnduNE9veHFSR0x1QUpGREhCOG1IaDNsYnJNYTlJSTVpRExsY2RYeG15MEZLUXFsWkVnVkNOMW5yQmNmeTBYWWJDdER6eGozd3NHYQ?oc=5","date":"2025-03-14","type":"regulatory","source":"European Pharmaceutical Review","summary":"EC approves Rytelo for LR- MDS-related anaemia - European Pharmaceutical Review","headline":"EC approves Rytelo for LR- MDS-related anaemia","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE12VTQ3N2ZNXzRvazNkSEJuMTc2OUJQS25LSVFmU1lBUWx0RWFvS0hzVHQzbkxBME8wSG8xZUJJM1h1dzhreVJROVRjcUpqZmp6NnZCa2k1aVFWQVhWWWZ2dUEzMTVxc1Y5SXc?oc=5","date":"2025-01-31","type":"regulatory","source":"Wiley Online Library","summary":"Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies - Platzbecker - 2025 - HemaSphere - Wiley Online Library","headline":"Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on c","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE55NGVFSWJsNFhWbFdrYnBtajhsMkZvMXo0Tk1LWGZ2Yl9lNllrYVZ2QmM0SHhUNVZNbkVCOWN0d21BV0hjOUpyMno0SkR1eFR3aVM3OUNEbjduRnhZUEVZ?oc=5","date":"2022-07-22","type":"trial","source":"nature.com","summary":"Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis - nature.com","headline":"Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1MSHMtNndhZHRUT21JRl9lejI5T1M2NkVURlpnUnA3d2RxTG9wWDZ4SkEyNzVsS3hHckhISW4xOHZsUF9ZLU5aSWJoZ085NUl0SjEwVy1nV1dWbmJSalJn?oc=5","date":"2022-02-26","type":"pipeline","source":"nature.com","summary":"Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis - nature.com","headline":"Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9KOEs4SDVobTVRNk9VMzZnUE5Pb2JMaDRLNEdWazBlRHJCcGYyYjFtUElRWmNKc1BZM0NidFkzYTQ1dS1hWEUyV2dUNUlFeG5CcWxGaEpZcmtTTUdUbEFr?oc=5","date":"2020-01-08","type":"pipeline","source":"NEJM","summary":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes - NEJM","headline":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9UVTdlRWRnX3dkSUNQdTNEdjFlYjI2YUVWUGYwRklnZFlzUXl5TnlKZHVxdVQ5QmdZTnI1WnZFb2pkUWRETkhNdzdibXU3aGloUXZUZ2JKUEtycS1XaFNRTg?oc=5","date":"2020-01-08","type":"pipeline","source":"NEJM","summary":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes - NEJM","headline":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE5GRXB0SFJFMjlnd1FSMGxTd2VSZTQ1NUU2NDltcWNCdm1BMkdzcG5ISzR1Nld5M2R4OE83Nm5sazJLUkdsMld2ZmRFX0JYazhmR1FPOXR2RHZkaVlwZVE?oc=5","date":"2019-12-03","type":"pipeline","source":"nature.com","summary":"Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents - nature.com","headline":"Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patie","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}